4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.79 +1.70%

+$0.16 today

Market cap
$596.08M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.81M

Average 0.77M

Income Statement

Follow revenue through to earnings.

Revenue

$85.21M

FY 2025 · Annual

+230194.6% YoY

Operating Income

-$159.55M

FY 2025 · Annual

Net Income

-$140.11M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

FDMT Earnings Waterfall · TTM

NASDAQ:FDMT · Revenue to Net Income

Key Ratios

EPS$-2.66
Gross Margin-92957.4%
Net Margin-107454.0%
P/E Ratio0.1
P/S Ratio4866.3

Analysis

$88.2M of revenue converted into -$160.9M of net income for the selected period. Gross margin is -92957.4% and net margin is -107454.0%, showing how much revenue survives after costs and taxes. EPS is $-2.66, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipOct 20, 2026
4Statement of changes in beneficial ownershipOct 7, 2026

How much revenue does FDMT generate?

4D Molecular Therapeutics, Inc. (FDMT) reported $85.21M of revenue in fiscal 2025.

Is FDMT profitable?

4D Molecular Therapeutics, Inc. (FDMT) reported -$140.11M of net income, with a net margin of -164.4%.